The recurrence rate of early stage poorly differentiated endometrioid adenocarcinoma is not accurately determined, as described in the 2022 NCCN Clinical Practice Guidelines for Uterine Oncology (1st ed.) The postoperative recurrence rate for patients with stage I and stage II endometrial cancer is approximately 15%, with the majority of recurrences occurring within 3 years of treatment. 50% to 70% of recurrences are symptomatic. Patients with endometrial cancer are advised to undergo regular review.
Hypofractionated endometrioid adenocarcinoma is a malignant disease with a relatively high degree of malignancy and a certain recurrence rate after treatment. According to the 2022 NCCN Clinical Practice Guidelines for Uterine Tumors (1st Edition), the postoperative recurrence rate for patients with stage I and II endometrial cancer is approximately 15%, with most recurrences occurring within 3 years of treatment.
Recurrence is symptomatic in 50% to 70% of endometrial cancer patients. Recurrences confined to the vagina or pelvis continue to do well after treatment. Isolated vaginal recurrences have a 5-year survival rate of 50% to 70% after radiation therapy. Recurrences beyond the vagina or pelvic lymph nodes have a poorer prognosis. Treatment of recurrence correlates with the location of the recurrence and whether or not it has received prior radiotherapy.
If early endometrial cancer patients have undergone corresponding surgical treatment, they need to consult doctor regularly according to the doctor’s instruction to know their physical condition, keep a good mindset in normal life, and actively consult doctor for examination and treatment if any uncomfortable symptoms appear. Don’t treat it by yourself, so as not to delay or aggravate the condition.